PINNACLE PCL Trademark

Trademark Overview


On Monday, February 28, 2022, a trademark application was filed for PINNACLE PCL with the United States Patent and Trademark Office. The USPTO has given the PINNACLE PCL trademark a serial number of 97287809. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, June 13, 2024. This trademark is owned by Ultragenyx Pharmaceutical Inc.. The PINNACLE PCL trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science
pinnacle pcl

General Information


Serial Number97287809
Word MarkPINNACLE PCL
Filing DateMonday, February 28, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, June 13, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 23, 2023

Trademark Statements


NOT AVAILABLE"PCL"
Goods and ServicesResearch and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays; compiling and sharing of patient data for research purposes in the field of medical science

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 3, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameUltragenyx Pharmaceutical Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Party NameUltragenyx Pharmaceutical Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNovato, CA 94949

Trademark Events


Event DateEvent Description
Wednesday, December 14, 2022NON-FINAL ACTION WRITTEN
Thursday, March 3, 2022NEW APPLICATION ENTERED
Thursday, March 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 12, 2022ASSIGNED TO EXAMINER
Wednesday, December 14, 2022NON-FINAL ACTION E-MAILED
Wednesday, December 14, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, March 9, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 9, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 9, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 20, 2023SOU EXTENSION 1 FILED
Wednesday, December 20, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, December 20, 2023SOU EXTENSION 1 GRANTED
Thursday, June 13, 2024SOU TEAS EXTENSION RECEIVED
Friday, August 2, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, August 2, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 2, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, August 2, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, June 13, 2024SOU EXTENSION 2 FILED
Friday, December 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 13, 2024SOU EXTENSION 2 GRANTED